Why is Aspira Pathlab falling/rising?

As of 17-Jul, Aspira Pathlab & Diagnostics Ltd is experiencing a decline in its stock price, currently at 51.52, which reflects a decrease of 0.98 or 1.87%. The stock has underperformed its sector today by 2.24%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 63.63% compared to the 5-day average. Over the past week, the stock has decreased by 3.70%, and it has seen a substantial decline of 12.90% over the past month, contrasting sharply with its impressive 61.50% return over the past year.
In the broader market context, while the stock has outperformed the BSE500 index over the past year, it has struggled recently compared to the benchmark, which has gained 0.83% in the same timeframe. The company's positive performance in terms of net sales and profits, along with an attractive valuation, suggests potential for growth; however, concerns about weak long-term fundamental strength and the company's ability to service its debt may be contributing to the current downward pressure on the stock price. The combination of these factors indicates that despite a strong historical performance, recent trends and investor sentiment are leading to a decline in Aspira Pathlab's stock price.